Sedation in the intensive care unit with remifentanil/propofol versus midazolam/fentanyl: a randomised, open-label, pharmacoeconomic trial

Table 3 Adverse event profile

	Remifentanil/propofol (n = 40)	Midazolam/fentanyl (n = 39)	P value^a
Any adverse event	23	24	NS
Any drug-related adverse event	9	2	<0.05
Shivering	8	2	NS
Pain	2	0	NS
Any serious adverse event	4	6	NS
Any drug-related serious adverse event	0	0	NS
Most commonly occurring adverse events (≥ 5% of patients)
Shivering	14	6	NS
Delirium	7	9	NS
Pain	3	0	NS
Tachycardia	2	0	NS
Neuropathy (nerve injury, e.g., by compression)	1	2	NS
Respiratory insufficiency	0	3	NS
Hypotension	3	0	NS
Haemorrhage	2	2	NS

Values are number of patients with event; multiple entries per patient possible.
^aFisher's exact test, two tails, significance level 0.05. NS, not significant.

ISSN: 1364-8535